Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

BACKGROUND: Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafenib and that of regorafenib in real-life, specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Young Mi, Yoon, K. T., Cho, Mong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130266/
https://www.ncbi.nlm.nih.gov/pubmed/34006248
http://dx.doi.org/10.1186/s12885-021-08124-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130266/
https://www.ncbi.nlm.nih.gov/pubmed/34006248
http://dx.doi.org/10.1186/s12885-021-08124-9

Ejemplares similares